Ocugen (OCGN) is climbing 5% after investment bank H.C. Wainwright raised its price target on the shares to $8 from $7. OCGN, ...

Pegcetacoplan (Syfovre) is the first FDA-approved drug to slow the progression of GA. It’s a shot you get in your eye every month or every other month. We now have the approval of a second ...

Signs and symptoms of age-related macular degeneration (AMD) are important to spot to prevent further deterioration of sight.

chronic inflammatory state inside the back of the eye that’s causing breakdown of the ocular tissue, breakdown of the retinal outer layers, and we think that’s why pegcetacoplan is effective ...

"Our results provide some guidance on treating GA patients with the recently approved intravitreal pegcetacoplan [Syfovre ... better suited for observation. Eyes with GA ≤1 mm from the foveal ...

It also asserted that the injections into the eye “carry a significant risk ... the latest appeal in the EU by the end of the year. Pegcetacoplan is approved in a subcutaneous form as Empaveli ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan ... Centre for Eye Research Australia. “The approval of SYFOVRE is a ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

European regulators on Friday upheld its negative opinion on Apellis Pharmaceuticals' (NASDAQ:APLS) proposed treatment for its eye disease ... company's intravitreal pegcetacoplan, a treatment ...

(Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan ... Centre for Eye Research Australia. "The approval of SYFOVRE is a historic ...